Search

Displaying results 2921 - 2930 of 4359 in total
  1. Drug

    Nedaplatin

    go.drugbank.com/drugs/DB13145
    ApprovedInvestigational

    Nedaplatin is a second generation platinum analog . It is less nephrotoxic than DB00515 but has proven equally effective. It was approved for use in Japan in 1995.

  2. Drug

    D-Treitol

    go.drugbank.com/drugs/DB03278
    Experimental

    It is twice as sweet as sucrose and can be used as a coronary vasodilator. [PubChem]

  3. Drug

    Novobiocin

    go.drugbank.com/drugs/DB01051
    ApprovedInvestigationalVet approvedWithdrawn

    Novobiocin is an antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase and blocks adenosine triphosphatase (ATPase) activity. (From Reynolds, Martindale The ...

  4. Drug

    Somatrogon

    go.drugbank.com/drugs/DB14960
    ApprovedInvestigational

    [L47153,L47158] Somatrogon is available as a once-weekly subcutaneous injection.[L39080,L47153] … growth hormone caused by growth hormone deficiency, marking Canada as the first country to approve this drug.

  5. Drug

    Cipepofol

    go.drugbank.com/drugs/DB16295
    ApprovedInvestigational

    [L63809] Haisco describes it as the first China-originated innovative intravenous anesthetic to enter the global market. … Cipepofol is an intravenous general anesthetic of the alkylphenol class, supplied as a sterile lipid emulsion, which is thought to act by positively modulating the inhibitory function of GABA at ligand-gated

  6. Drug

    Prednisolone phosphate

    go.drugbank.com/drugs/DB14631
    ApprovedInvestigationalVet approved

    Prednisolone phosphate is a glucocorticoid similar to cortisol used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone phosphate was granted FDA Approval on 19 December 1973.

  7. Drug

    Gedatolisib

    go.drugbank.com/drugs/DB11896
    ApprovedInvestigational

    Celcuity describes gedatolisib as the first FDA-approved therapy to inhibit the pathway comprehensively across all class I PI3K isoforms and both mTOR complexes. … [L63927] Its approval also addresses a population defined by the absence of a biomarker, as patients with PIK3CA wild-type disease were not eligible for the PI3Kα-selective options.

  8. Drug

    Eslicarbazepine acetate

    go.drugbank.com/drugs/DB09119
    ApprovedInvestigational

    Eslicarbazepine acetate (ESL) is an anticonvulsant medication approved for use in Europe, the United States and Canada as an adjunctive therapy for partial-onset seizures that are not adequately controlled … Eslicarbazepine acetate is marketed as Aptiom in North America and Zebinix or Exalief in Europe. It is available in 200, 400, 600, or 800mg tablets that are taken once daily, with or without food.

    Categories: Voltage-Gated Sodium Channel Blockers
  9. Drug

    Sonrotoclax

    go.drugbank.com/drugs/DB18753
    ApprovedInvestigational

    [L56193,L56194] The application received priority review, breakthrough therapy designation, and orphan drug designation, and was reviewed under Project Orbis with the EMA as an official observer. … [L56193,A275521] Sonrotoclax was rationally designed as a BH3 mimetic with a shallow and broad interaction with the P2 pocket of BCL-2, achieved through a novel 7-azaspiro[3.5]nonane linker; this binding

  10. Drug

    Florquinitau (18F)

    go.drugbank.com/drugs/DB19215
    Approved

    Florquinitau F 18 is a radioactive diagnostic drug used as a fluorine-18–labeled positron emission tomography (PET) tracer. … [L64052] Florquinitau F 18, also known as MK-6240, was approved by the FDA on August 14, 2026 for PET of the brain in adults with cognitive impairment who are being evaluated for Alzheimer's disease